Soligenix, Inc. (NASDAQ:SNGX) Short Interest Up 21.0% in December

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 44,400 shares, a growth of 21.0% from the November 30th total of 36,700 shares. Based on an average daily trading volume, of 105,000 shares, the short-interest ratio is currently 0.4 days. Approximately 1.8% of the company’s stock are short sold.

Soligenix Price Performance

NASDAQ SNGX opened at $2.91 on Tuesday. The firm has a market cap of $7.30 million, a P/E ratio of -0.39 and a beta of 1.79. The stock’s 50-day moving average is $3.40 and its two-hundred day moving average is $3.81. Soligenix has a fifty-two week low of $1.83 and a fifty-two week high of $19.20.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Soligenix stock. Armistice Capital LLC purchased a new stake in Soligenix, Inc. (NASDAQ:SNGX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 80,000 shares of the biopharmaceutical company’s stock, valued at approximately $206,000. Armistice Capital LLC owned 8.11% of Soligenix as of its most recent SEC filing. 3.60% of the stock is currently owned by institutional investors.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.